What we do
Corporate Governance Advisory Services
ESG Advisory Services
Merger & Acquisition Services
Capital Market Intelligence Services
Proxy Contests, Hostile Takeovers & Shareholder Activism Services
Proxy Solicitation Services
Retail Services and Additional Capabilities
Board of Director Services
Global Debt Services
SPAC Advisory Services
Services for Registered Funds: Mutual Funds, ETFs and Closed-End Funds
Strategic Communications
Corporate Communications
Crisis and Issues management
Investor Relations
Transaction Communication
Research
Client Portal

Recent Mergers and Acquisitions

BridgeBio Pharma Acquires 36.35% of Eidos Therapeutics Shares

BridgeBio Pharma (Nasdaq: BBIO), a genetic-disease biotechnology company, is acquiring the remaining 36.35% of shares outstanding in Eidos Therapeutics (Nasdaq: EIDX), a specialized clinical-stage biotechnology company, for $1.03 billion.

Morrow Sodali acted as the proxy solicitor for the bidder in this transaction.

Find more information here.

Topics

BridgeBio Pharma Acquires 36.35% of Eidos Therapeutics Shares

Topics

BridgeBio Pharma (Nasdaq: BBIO), a genetic-disease biotechnology company, is acquiring the remaining 36.35% of shares outstanding in Eidos Therapeutics (Nasdaq: EIDX), a specialized clinical-stage biotechnology company, for $1.03 billion.

Morrow Sodali acted as the proxy solicitor for the bidder in this transaction.

Find more information here.

© 2016 - 2023 Morrow Sodali